Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCureNXTC -4.76%28 3-Year EBITDA Growth Rate is 14.40% as of Jun. 2026. GuruFocus rates NXTC with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,127 Biotechnology companies, NextCure ranks worse than 50.49% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -0.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of NextCure was 14.40% per year. The lowest was -18.70% per year. And the median was -0.65% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
NextCure 3-Year EBITDA Growth Rate Related Terms
NXTC vs CVM, PLRZ, BYSI: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, NextCure's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where NextCure's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.40% mean?
NextCure (NXTC) has a 3-Year EBITDA Growth Rate of 14.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NextCure and its competitors. According to the industry distribution chart, NextCure ranks #569 out of 1127 companies in the Biotechnology industry, placing it in the top 50.5%.
Is NextCure's 3-Year EBITDA Growth Rate too high?
NextCure's current 3-Year EBITDA Growth Rate is 14.40%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. NextCure's value of 14.40% is 1.4% below this industry median. Based on the distribution chart, NextCure ranks #569 out of 1127 companies in the Biotechnology industry, which is below the industry midpoint. Overall, NextCure has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does NextCure's 3-Year EBITDA Growth Rate compare to CVM and PLRZ?
According to the Biotechnology industry distribution chart, NextCure ranks #569 out of 1127 companies for 3-Year EBITDA Growth Rate. This places NextCure in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. NextCure's value of 14.40% is 1.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NextCure's current 3-Year EBITDA Growth Rate of 14.40% is 1.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NextCure and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NextCure's current 3-Year EBITDA Growth Rate is 14.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCure stock overvalued right now?
NextCure (NXTC) has a current 3-Year EBITDA Growth Rate of 14.40%. The current 3-Year EBITDA Growth Rate is 14.40% and 1.4% below the Biotechnology industry median of 14.60. NextCure's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For NextCure (NXTC), the current 3-Year EBITDA Growth Rate is 14.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
28GF Score
Get the complete analysis for NXTC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXTC has been successfully added to your 
